Document is current
Any future updates will be listed below
-
Authors
de Wolf, Bas
Oghabian, Ali
Akinyi, Maureen V https://orcid.org/0000-0001-9533-3059
Hanks, Sandra
Tromer, Eelco C
van Hooff, Jolien J E
van Voorthuijsen, Lisa
van Rooijen, Laura E
Verbeeren, Jens
Uijttewaal, Esther C H
Baltissen, Marijke P A
Yost, Shawn
Piloquet, Philippe
Vermeulen, Michiel https://orcid.org/0000-0003-0836-6894
Snel, Berend
Isidor, Bertrand
Rahman, Nazneen
Frilander, Mikko J https://orcid.org/0000-0002-1732-4808
Kops, Geert J P L https://orcid.org/0000-0003-3555-5295
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding
Cancer Genomics Centre
Wellcome Trust (100210/Z/12/Z)
Sigrid Jusélius Foundation
Jane and Aatos Erkko Foundation
Academy of Finland (1308657)
The Dutch Research Council (OCENW.KLEIN.182)
- License Information
-
More Information
Article History
Received: 14 August 2020
Revised: 16 April 2021
Accepted: 19 April 2021
First Online: 19 May 2021
Conflict of interest
: Nazneen Rahman is a non‐executive director of AstraZeneca. The other authors declare no competing interests.
